iSpecimen stock faces a pivotal October 9 vote on dilution and AI deal

Published on 10/05/2026 at 09:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

iSpecimen stock faces an October 9, 2026 vote covering dilution, a reverse split and a USD 4.5 million AI asset deal. Q2 revenue was USD 151,940.

ISPC, US45032V3069, Illustration mit AI erstellt.

iSpecimen stock (ISIN US45032V3069) was last at USD 1.08 on Nasdaq on October 2, 2026, down 5.26 percent from the prior close, while its market capitalization stood at USD 2.7 million. The immediate catalyst is a special shareholder meeting scheduled for October 9, 2026, where investors will vote on financing authority, a potential reverse split and a Foldlab AI asset acquisition.

October 9 vote carries dilution risk

According to StockTitan, the September 14, 2026 proxy calls for approval of five proposals. They include issuance authority above Nasdaq's 19.99 percent threshold, future equity-linked financing at discounts of up to 80 percent from the applicable lowest VWAP, a reverse split between 1-for-10 and 1-for-100, and the proposed Foldlab AI transaction.

The proposed acquisition carries total consideration of USD 4.5 million, split between USD 2.0 million in cash and USD 2.5 million in iSpecimen stock. The proxy states that the stock portion would remain in escrow for five years, making the transaction strategically relevant but also closely tied to future share issuance.

Second-quarter revenue falls to USD 151,940

For the quarter ended June 30, 2026, iSpecimen reported revenue of USD 151,940 and a net loss of USD 1.36 million, according to ToAlpha. Revenue was down 85.6 percent year over year, while diluted EPS was negative USD 0.98, putting operating performance alongside the financing questions before the shareholder vote.

The balance sheet showed USD 4.4 million in cash at June 30, 2026, while operating cash flow was negative USD 689,625 in the quarter. Those figures make access to capital and the terms of any additional issuance central to the investment case.

Nasdaq deadline arrives in November

iSpecimen disclosed on September 8, 2026 that Nasdaq had granted the company an extension until November 25, 2026 to regain compliance with the exchange's stockholders' equity requirement, according to SEC.gov. The filing says the extension has no immediate effect on trading, but failure to demonstrate compliance could expose the company to delisting proceedings.

ISPC stock remains below Nasdaq threshold

At USD 1.08 on October 2, 2026, iSpecimen stock was only USD 0.08 above Nasdaq's USD 1.00 minimum bid-price level cited in the proxy. The October 9 vote and the November 25 compliance deadline therefore give the stock two dated corporate checkpoints.